🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  2. Thoracoscopic Bullectomy Surgery

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stability During Surgical Operation

    phase 3 other active

    1 trial

  3. Tibsovo 250 mg film-coated tablets

    The George Institute

    ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  4. Tildrakizumab Placebo Solution for Injection, TILDRAKIZUMAB

    Lacuna Pharma Pty Ltd

    Moderate to Severe Genital Psoriasis

    phase 3 small molecule active

    1 trial

  5. Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab

    Lacuna Pharma Pty Ltd

    Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis

    phase 3 small molecule active

    1 trial

  6. Timolol vehicle, Bimatoprost SR sham applicator, Timolol, Bimatoprost SR, Bimatoprost SR

    AbbVie Deutschland GmbH & Co. KG

    Ocular hypertension, Open-angle glaucoma

    phase 3 small molecule active

    1 trial

  7. Tiragolumab

    Hoffmann-La Roche

    Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  8. Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  11. Tirzepatide

    Eli Lilly and Company

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  12. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  13. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Carcinoma

    phase 3 small molecule active

    1 trial

  14. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  15. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  16. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  17. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  18. Tislelizumab

    BeiGene

    Recurrent or Metastatic Nasopharyngeal Cancer

    phase 3 small molecule completed

    1 trial

  19. Tislelizumab

    BeiGene

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  20. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Classical Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  21. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  22. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule completed

    1 trial

  23. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  24. Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources